We are Committed to being a Collaborative Platform for Innovative Biotech Companies from around the World.
Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.
An Innovative Idea is All You Need
Our leading CRO platform is productive and efficient and it enables both quick and quality drug candidate discovery
Average time to invest: 2 months; Introductions for later-stage funding and financial advice
Business Partners Venture Advisors
Assistance in procuring internal or external resources
“Back-office” support (HR, Accounting, Procurement, BD, Financing, etc.)
We invest in some of the most innovative founders to build a unique portfolio covering a wide range of indications and drug types.
Read the most up to date information about us and our partners.
Anji’s clinical pipeline is led by delayed-release metformin (ANJ900 – Ph3) for effective glucose management in patients with typ...
Promoting the R&D of VivaVision’s Innovative Drugs
The enrollment of the first patient marks the successful transformation of QureBio into an innovative pharmaceutical company in the c...
The MCL1 target has been widely viewed as undruggable – Anji sees it as undone
Complementary technologies combined to enable streamlined design and production of next-generation therapeutic proteins for disease-spe...
To treat type 2 diabetes patients with kidney disease